Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iconovo ABOSTO:ICO -2.78%34 Forward PE Ratio is 28.25 as of Jul. 16, 2026. GuruFocus rates OSTO:ICO with a GF Score™ of 34/100 and a GF Value™ of kr0.27 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 392 Medical Devices & Instruments companies, Iconovo AB ranks worse than 69.9% on this metric.
Iconovo AB (OSTO:ICO) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Iconovo AB Forward PE Ratio Related Terms
Iconovo AB Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Iconovo AB's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iconovo AB Forward PE Ratio Chart
Iconovo AB Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
41.40
28.38
Iconovo AB Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
Forward PE Ratio
41.40
28.10
21.81
37.00
28.38
OSTO:ICO vs ABT, SYK, MDT: Forward PE Ratio Comparison
For the Medical Devices subindustry, Iconovo AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iconovo AB Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Iconovo AB's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Iconovo AB's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Iconovo AB (OSTO:ICO) has a Forward PE Ratio of 28.25 as of Jul. 16, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Iconovo AB and its competitors. According to the industry distribution chart, Iconovo AB ranks #274 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 69.9%.
Is Iconovo AB's Forward PE Ratio too high?
Iconovo AB's current Forward PE Ratio is 28.25. The Medical Devices & Instruments industry median Forward PE Ratio is 19.26. Iconovo AB's value of 28.25 is 46.7% above this industry median. Based on the distribution chart, Iconovo AB ranks #274 out of 392 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Iconovo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Iconovo AB ranks #274 out of 392 companies for Forward PE Ratio. This places Iconovo AB in the lower half of its industry. The industry median Forward PE Ratio is 19.26. Iconovo AB's value of 28.25 is 46.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.26, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iconovo AB's current Forward PE Ratio of 28.25 is 46.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Iconovo AB and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iconovo AB's current Forward PE Ratio is 28.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.27, compared to a current price of kr1.05 — trading 288.9% above its estimated fair value. The current Forward PE Ratio is 28.25 and 46.7% above the Medical Devices & Instruments industry median of 19.26. Iconovo AB's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current Forward PE Ratio is 28.25 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iconovo AB (OSTO:ICO) Overvalued in 2026?
Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued.
The current stock price of kr1.05 is trading 288.9% above its estimated GF Value™ of kr0.27.
GuruFocus considers Iconovo AB to be Significantly Overvalued.
Key valuation signals for OSTO:ICO:
Forward PE Ratio: 28.25
GF Value™: kr0.27 vs. price of kr1.05 (288.9% above fair value)
Industry Position: 46.7% above the Medical Devices & Instruments median (#274 of 392)
No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
34GF Score
Get the complete analysis for OSTO:ICO
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ICO has been successfully added to your 
